PNC-27: Compound Profile

PNC-27 is one of the more frequently referenced chimeric p53-penetratin peptides in the protein-interaction literature, and it is a mechanism story rather than an outcome story: the research follows how a designed sequence binds a specific oncoprotein and behaves at the cell membrane. This profile covers what the peptide is, the receptor-and-membrane mechanism the studies attribute to it, and how it is handled in the laboratory. For the transparency posture that governs how it is described here, see research compliance and quality standards.

What is PNC-27?#

PNC-27 is a synthetic chimeric peptide built from two joined parts. The first is a domain derived from the p53 tumor-suppressor protein — the region p53 uses to contact its negative regulator HDM-2 (the human homolog of MDM2). The second is a penetratin-type leader sequence, a membrane-residency element adapted from the Antennapedia homeodomain that anchors the construct at lipid membranes. Fusing the two produces a 32-amino-acid research peptide whose reported behavior comes from how those two halves act together, so the reliable identity anchor is the full sequence and its chemical record rather than any single functional label.

What does the research literature study?#

The PNC-27 literature is organized around a single mechanistic claim: that the peptide binds HDM-2 in a p53-like way and, where HDM-2 sits at the plasma membrane, drives selective pore formation. The foundational structural work reported that PNC-27 adopts an HDM-2-binding conformation resembling the native p53 contact and colocalizes with membrane HDM-2 in cancer-cell models. A later NMR and pore-formation study resolved the p53 peptide-like binding structure and characterized the membrane-pore step in more detail. Subsequent preclinical work extended the model across cell systems — leukemia-cell models and ovarian-carcinoma cell lines reported that membrane HDM-2 expression tracks with the observed cytolysis in culture, with normal cells used as the contrast condition. A 2024 mechanistic account frames the transmembrane-pore step as the defining feature of the system. All of this is preclinical research conducted in cell and biochemical models, and none of it speaks to effects in people.

Where PNC-27 sits among research peptides#

PNC-27 belongs to the protein-interaction and membrane-active branch of the research-peptide space rather than to the signaling classes Nexara documents elsewhere. Where a peptide like TB-500 is defined by binding an intracellular protein target (actin), PNC-27 is defined by a designed protein contact (the p53–HDM-2 interface) coupled to a membrane-residency element. That combination is what places it in the chimeric, structure-driven category: its identity comes from an engineered binding conformation plus a membrane leader, not from mimicking an endogenous hormone or growth factor. It is studied as a probe of protein-protein interaction and membrane behavior in cell models.

Handling and storage#

PNC-27 is supplied as a white to off-white lyophilized solid and dissolved prior to use. Being a longer 32-residue peptide with a hydrophobic membrane-active segment, it follows the same laboratory handling as the rest of the catalog: the reconstitution primer covers solvent selection and avoiding aggregation, while the cold-chain article covers how stability changes once the powder is in solution.

Sources and further reading#

• Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes (PMID 20080680): the foundational structural report on the HDM-2-binding conformation and membrane colocalization. PNAS 2010.
• PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis (PMID 35625682): NMR-resolved binding structure and characterization of the membrane-pore step. Biomedicines 2022.
• Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells (PMID 32878773): preclinical leukemia-cell model linking membrane HDM-2 to the observed cytolysis. Anticancer Research 2020.
• Anti-Cancer Tumor Cell Necrosis of Epithelial Ovarian Cancer Cell Lines Depends on High Expression of HDM-2 Protein in Their Membranes (PMID 33067207): ovarian-carcinoma cell-line study on membrane HDM-2 dependence. Annals of Clinical & Laboratory Science 2020.
• Poptosis or Peptide-Induced Transmembrane Pore Formation: A Novel Way to Kill Cancer Cells without Affecting Normal Cells (PMID 38927351): mechanistic account framing the transmembrane-pore step. Biomedicines 2024.
• PNC-27, PubChem CID 16201774: chemical identity record for the chimeric peptide.